<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26702">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759120</url>
  </required_header>
  <id_info>
    <org_study_id>1504016087</org_study_id>
    <nct_id>NCT02759120</nct_id>
  </id_info>
  <brief_title>CleanUP IPF for the Pulmonary Trials Cooperative</brief_title>
  <acronym>CleanUp-IPF</acronym>
  <official_title>Study of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of standard care, versus standard of care
      plus antimicrobial therapy (co-trimoxazole or doxycycline), on clinical outcomes in patients
      diagnosed with idiopathic pulmonary fibrosis (IPF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, un-blinded, phase III, multi-center clinical trial of an antimicrobial
      therapy strategy in idiopathic pulmonary fibrosis patients. Our overall hypothesis is that
      reducing harmful microbial impact with antimicrobial therapy will reduce the risk of
      non-elective, respiratory hospitalization or death in patients with Idiopathic Pulmonary
      Fibrosis (IPF).

      Subjects will be randomized 1:1 to either receive a prescription drug voucher for oral
      antimicrobial therapy in the form of one double strength 160 milligrams (mg)
      trimethoprim/800mg sulfamethoxazole (double strength co-trimoxazole) twice daily plus folic
      acid 5 mg daily OR doxycycline 100mg once daily if weight &lt; 50 kilograms (kg) or 100mg twice
      daily if weight &gt; 50 kg. Patients randomized to receive antimicrobial therapy will be given
      co-trimoxazole unless they have an allergy, contraindication to co-trimoxazole, renal
      insufficiency (glomerular filtration rate (GFR) &lt; 30 milliliters (ml)), are hyperkalemic
      (potassium &gt; 5 milliequivalents(mEq)/liter(L)), or are concomitantly taking an angiotensin
      converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or potassium sparing
      diuretic in which case they will receive doxycycline.

      Participation in this study will be between 12 months and 42 months depending on time of
      enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first non-elective, respiratory hospitalization or all-cause mortality</measure>
    <time_frame>Randomization to event (up to 42 months)</time_frame>
    <description>Days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to death from any cause</measure>
    <time_frame>Randomization to event (up to 42 months)</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first non-elective, respiratory hospitalization</measure>
    <time_frame>Randomization to event (up to 42 months)</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first non-elective, all-cause hospitalization</measure>
    <time_frame>Randomization to event (up to 42 months)</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of non-elective respiratory hospitalizations</measure>
    <time_frame>Randomization to event (up to 42 months)</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of non-elective all-cause hospitalizations</measure>
    <time_frame>Randomization to event (up to 42 months)</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Change in forced vital capacity (FVC)</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Percent change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change in diffusion capacity of lungs for carbon monoxide (DLCO)</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Percent change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of respiratory infections</measure>
    <time_frame>Randomization to event (up to 42 months)</time_frame>
    <description>Number of respiratory infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in University of California San Diego (UCSD)-Shortness of Breath Questionnaire</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Difference in score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fatigue Severity Scale score</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Difference in score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leicester Cough Questionnaire score</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Difference in score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in European Quality of Life-5 dimensions (EQ-5D) score</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Difference in score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in short form-12 health survey (SF-12) score</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Difference in score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ICEpop (Investigating Choice Experiments for the Preferences of Older People) CAPability measure for Older people (ICECAP-O) score</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Difference in score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Antimicrobial therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Co-trimoxazole OR doxycycline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of care for patients with IPF for comparison</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antimicrobial therapy: Co-trimoxazole or Doxycycline</intervention_name>
    <description>160mg trimethoprim/800mg sulfamethoxazole (double strength co-trimoxazole) twice daily plus folic acid 5 mg daily OR doxycycline 100mg once daily if weight &lt; 50 kilograms or 100mg twice daily if weight &gt; 50 kilograms for up to 42 months</description>
    <arm_group_label>Antimicrobial therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention: Standard of Care</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. â‰¥ 40 years of age

          2. Diagnosed with idiopathic pulmonary fibrosis (IPF) by enrolling investigator

          3. Signed informed consent

        Exclusion Criteria:

          1. Received antimicrobial therapy in the past 30 days

          2. Contraindicated for antibiotic therapy, including but not exclusive to:

               1. Allergy or intolerance to both tetracyclines AND trimethoprim, sulfonamides or
                  their combination

               2. Allergy or intolerance to tetracyclines AND known potassium level &gt; 5 mEq/L in
                  the past 6 months.

                    -  If the enrolling physician feels the potassium level has normalized,
                       documentation to that effect must be provided.

               3. Allergy or intolerance to tetracyclines AND concomitant use of
                  angiotensin-converting enzyme (ACEI), angiotensin II receptor blockers (ARB), or
                  potassium sparing diuretic

               4. Allergy or intolerance to tetracyclines AND known glucose-6-phosphate
                  dehydrogenase deficiency

               5. Allergy or intolerance to tetracyclines AND untreated folate or B12 deficiency

               6. Allergy or intolerance to tetracyclines AND known renal insufficiency (defined
                  as a glomerular filtration rate (GFR) &lt; 30 ml within the previous 6 months)

                    -  If the enrolling physician feels the renal dysfunction has resolved,
                       documentation to that effect must be provided.

          3. Pregnant or anticipate becoming pregnant

          4. Use of an investigational study agent for IPF therapy within the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Martinez, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell Medical Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fernando Martinez, MD, MS</last_name>
    <phone>212-746-6420</phone>
    <email>fjm2003@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kevin Anstrom, PhD, MS, BS</last_name>
    <phone>919-668-8902</phone>
    <email>kevin.anstrom@duke.edu</email>
  </overall_contact_backup>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 8, 2017</lastchanged_date>
  <firstreceived_date>April 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Pulmonary Fibrosis</keyword>
  <keyword>IPF</keyword>
  <keyword>pulmonary fibrosis</keyword>
  <keyword>antimicrobial therapy</keyword>
  <keyword>doxycycline</keyword>
  <keyword>co-trimoxazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
